Corporate News Details
Emcure Pharmaceuticals reduces prices of its weight management drug Poviztra' in India
(02-Apr-26 17:46)
Emcure Pharmaceuticals has announced the price revision of its weight management drug Poviztra' (semaglutide injection) across India.
The reduced price would be starting at Rs. 3,999/- per month (4 weekly doses).
The innovator Semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. It comes in a state-of-the-art pen device that provides the convenience of simple administration and precise dosing.
As the first Indian company to exclusively distribute and commercialise Poviztra', a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy at the revised price.
